Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The dimeric copper peptide D-CuP showed superior antioxidant properties compared to M-CuP, leading to a notable decrease in relative fluorescence intensity
It produced an average weight loss of 22.7% over 68 weeks in its Phase 3 REDEFINE 1 trial, the highest reported for any Novo Nordisk obesity drug to date
10.1111/jfbc.14039 J Food Biochem
Notably, the ongoing phase I/II trial of XNW5004, an EZH2 inhibitor, in combination with pembrolizumab (NCT06022757) exemplifies the effort to reprogram epigenetic states and restore ICB sensitivity in solid tumors resistant to conventional treatments
*The following information, as well as all statements and products on this website, have not been evaluated by the FDA and are not intended to diagnose, mitigate, treat, cure, or prevent any disease or health condition
When in doubt about combinations, consult the peptide safety guidelines and work with a qualified healthcare provider
US$ 26.94
US$ 24.52
US$ 22.98
US$ 20.15
US$ 28.37
US$ 20.56
US$ 22.42
US$ 23.33
US$ 20.83
US$ 25.56
